학술논문
The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer
Document Type
Article
Author
Source
In: Therapeutic Advances in Medical Oncology . (Therapeutic Advances in Medical Oncology, 2020, 12)
Subject
Language
English
ISSN
17588359
17588340
17588340